Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

CXCL12 and CXCL13 Levels in Cerebrospinal Fluid (CSF) of Patients with CNS Lymphoma.

Lars Fischer, MD, Philipp Kiewe, MD, Sebastian Pfeiffer, MD, Hüsniye Cakiroglu, Eckhard Thiel, MD

Blood (2007) 110 (11): 1576.

https://doi.org/10.1182/blood.V110.11.1576.1576

Published: 2007

Journal Articles

Primary Central Nervous System Lymphoma (PCNSL): Intent-to-Treat Analysis of Monocenter Long-Term Experience.

Agnieszka Korfel, MD, Philipp Kiewe, MD, Lars Fischer, MD, Peter Mertus, PhD, Eckhard Thiel, PhD

Blood (2007) 110 (11): 1365.

https://doi.org/10.1182/blood.V110.11.1365.1365

Published: 2007

Journal Articles

Alemtuzumab but Not ATG Decreases Natural Killer (NK) Cell Activity towards Tumor Targets in the Early Phase after Allogeneic Stem Cell Transplantation.

Olaf Penack, MD, Lars Fischer, MD, Andrea Stroux, Chiara Gentilini, MD, Axel Nogai, MD, Arne Muessig, MD, Susanne Ganepola, MD, Eckhard Thiel, MD, Lutz Uharek, MD

Blood (2006) 108 (11): 2869.

https://doi.org/10.1182/blood.V108.11.2869.2869

Published: 2006

Journal Articles

High Anti-Tumor Activity of Natural Killer Cells after Non-Myeloablative Conditioning and Allogeneic Stem Cell Transplantation.

Lars Fischer, MD, Olaf Penack, MD, Andrea Stroux, Chiara Gentilini, MD, Eckhard Thiel, Lutz Uharek

Blood (2006) 108 (11): 5146.

https://doi.org/10.1182/blood.V108.11.5146.5146

Published: 2006

Journal Articles

Analysis of Factors Influencing Natural Killer (NK) Cell Activity during the Early Phase after Allogeneic Stem Cell Transplantation (SCT).

Lars Fischer, MD, Olaf Penack, MD, Chiara Gentilini, MD, Eckhard Thiel, MD, Uharek Lutz, MD

Blood (2005) 106 (11): 2192.

https://doi.org/10.1182/blood.V106.11.2192.2192

Published: 2005

Journal Articles

Quantification and Characterization of Peripheral Blood Natural Killer (NK) Cells Mediating Rituximab and Alemtuzumab Dependent Cytotoxicity.

Olaf Penack, MD, Lars Fischer, MD, Chiara Gentilini, MD, Anne M. Asemissen, MD, Carmen Scheibenbogen, MD, Eckhard Thiel, MD, Lutz Uharek, MD

Blood (2005) 106 (11): 2808.

https://doi.org/10.1182/blood.V106.11.2808.2808

Published: 2005

NARROW

CXCL12 and CXCL13 Levels in Cerebrospinal Fluid (CSF) of Patients with CNS Lymphoma.

Primary Central Nervous System Lymphoma (PCNSL): Intent-to-Treat Analysis of Monocenter Long-Term Experience.

Alemtuzumab but Not ATG Decreases Natural Killer (NK) Cell Activity towards Tumor Targets in the Early Phase after Allogeneic Stem Cell Transplantation.

High Anti-Tumor Activity of Natural Killer Cells after Non-Myeloablative Conditioning and Allogeneic Stem Cell Transplantation.

Analysis of Factors Influencing Natural Killer (NK) Cell Activity during the Early Phase after Allogeneic Stem Cell Transplantation (SCT).

Quantification and Characterization of Peripheral Blood Natural Killer (NK) Cells Mediating Rituximab and Alemtuzumab Dependent Cytotoxicity.

Email alerts

ASH Publications

American Society of Hematology

CXCL12 and CXCL13 Levels in Cerebrospinal Fluid (CSF) of Patients with CNS Lymphoma.

Primary Central Nervous System Lymphoma (PCNSL): Intent-to-Treat Analysis of Monocenter Long-Term Experience.

Alemtuzumab but Not ATG Decreases Natural Killer (NK) Cell Activity towards Tumor Targets in the Early Phase after Allogeneic Stem Cell Transplantation.

High Anti-Tumor Activity of Natural Killer Cells after Non-Myeloablative Conditioning and Allogeneic Stem Cell Transplantation.

Analysis of Factors Influencing Natural Killer (NK) Cell Activity during the Early Phase after Allogeneic Stem Cell Transplantation (SCT).

Quantification and Characterization of Peripheral Blood Natural Killer (NK) Cells Mediating Rituximab and Alemtuzumab Dependent Cytotoxicity.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only